by aisla@raikee.fi | Jan 31, 2020 | News
The latest open access paper about our hypoallergen development is available at Nature Scientific Reports. The paper, titled “Development of hypoallergenic variants of the major horse allergen Equ c 1 for immunotherapy by rational structure based...
by aisla@raikee.fi | Nov 1, 2019 | News
Desentum is about to initiate a first-in-human clinical trial with its birch pollen hypoallergen designed to improve immunotherapeutic treatment of birch pollen allergy. In a funding round arranged by Springvest Oy, the company raised 4 million euros that it intends...
by aisla@raikee.fi | Sep 18, 2019 | News
Preparations are currently being finalized for the first clinical study with DM-101 hypoallergen, Desentum’s lead product candidate for the treatment of birch pollen allergy. DM-101 (rBet v 1 dm) is a genetically engineered birch pollen allergen that is designed to...
by aisla@raikee.fi | Oct 29, 2018 | News
Desentum has been awarded a 1.9 M€ grant from the EIC pilot SME Instrument for a project titled AllergyVAX. The two-and-a-half-year project, starting at the end of 2018, includes early clinical trials of Desentum’s lead product candidate, an immunotherapeutic vaccine...
by aisla@raikee.fi | Sep 19, 2018 | News
Desentumin joukkorahoituskierros käynnistyi 17.9.2019 Desentum on aloittamassa kliiniset tutkimukset ensimmäisellä immunoterapeuttisella tuotteellaan, DM-101:llä, joka on suunnattu koivuallergian hoitoon. Tuotteella pyritään koivuallergian siedätyshoidon merkittävään...
by aisla@raikee.fi | Nov 29, 2017 | News
Desentum is progressing towards clinical stage with its first immunotherapeutic product targeting birch pollen allergy. It has raised approx. EUR 2.3 million in a crowd funding campaign arranged by a Finnish investment service company Kansalaisrahoitus. The funds...
